Two oral GLP-1s are now FDA-approved for weight loss: the Wegovy pill (oral semaglutide 25 mg) and Foundayo (orforglipron). That's more progress in six months than the previous six years produced. But the pipeline behind them is deep — and the next wave of oral obesity drugs aims to go further, combining multiple mechanisms in a single daily pill.
Not every candidate will make it. Drug development is expensive, slow, and full of late-stage failures. This article covers the oral obesity drugs currently in clinical trials, what their early data shows, and which ones were discontinued and why. No hype, just what we actually know.
Where We Stand Now
The two approved oral GLP-1s represent different generations of drug design. The Wegovy pill is a peptide-based GLP-1 with SNAC absorption technology — an impressive engineering solution with a fasting requirement trade-off. Foundayo is a small-molecule GLP-1 agonist with no food restrictions. Both produce clinically meaningful weight loss, but neither reaches the 20%+ weight loss that next-generation injectable combinations (like tirzepatide) achieve for many patients.
The pipeline drugs generally aim to close that gap — either by combining GLP-1 with other hormonal mechanisms, or by improving on the small-molecule approach to boost efficacy while maintaining the convenience of a daily pill.
The Candidates to Watch
Oral Amycretin / Zenagamtide
Phase 3Amycretin is the drug most likely to become the next oral obesity medication to reach the market. Novo Nordisk considers it their flagship next-generation obesity asset, and they initiated Phase 3 programs for both subcutaneous and oral formulations in Q1 2026. The company increasingly refers to the Phase 3 asset under its international nonproprietary name, zenagamtide.
What makes amycretin notable is its dual mechanism. Rather than combining two separate drugs (the approach CagriSema takes with cagrilintide + semaglutide), amycretin is a single molecule that activates both GLP-1 and amylin receptors. Amylin is a hormone co-secreted with insulin that enhances satiety through different neural pathways than GLP-1 alone. The result — at least in early trials — is significantly greater weight loss than GLP-1 alone.
The 22% weight loss figure comes from the injectable formulation. The oral formulation's Phase 2 data is earlier-stage but encouraging: the oral form produced meaningful weight loss that hadn't reached a plateau, suggesting the efficacy ceiling hadn't been hit yet at the doses tested. If oral amycretin can deliver even 15–18% weight loss in Phase 3, it would meaningfully exceed both current oral options.
Estimated timeline: Phase 3 results likely 2028–2029. FDA approval, if successful, could follow in 2029–2030.
Elecoglipron (AZD5004 / ECC5004)
Phase 1b/2AstraZeneca licensed this oral small-molecule GLP-1 from Shanghai-based biotech Eccogene in November 2023. It's a different chemical scaffold than orforglipron (Foundayo), and early Phase 1b topline data from China showed 5.8% weight loss over just four weeks with acceptable tolerability — a rapid rate of loss for such a short study duration.
The drug is moving into Phase 2, but it's still years away from potential FDA approval. AstraZeneca has significant resources to accelerate development, but early-phase data should be interpreted cautiously. Many drugs show promising short-term weight loss that doesn't scale linearly to longer trials.
Estimated timeline: Phase 2 data expected 2027. Phase 3 and potential approval could be 2030+ if development proceeds.
Danuglipron
DiscontinuedDanuglipron was Pfizer's attempt to compete in the oral GLP-1 space, and it produced genuinely competitive weight loss numbers in Phase 2 trials. The twice-daily formulation showed up to 13% placebo-adjusted weight loss at 32 weeks — roughly in the same range as Foundayo.
The problem wasn't efficacy. The twice-daily formulation had high discontinuation rates (22–34% at higher doses) due to GI side effects. Pfizer developed a once-daily extended formulation to address tolerability, and that reformulation met its pharmacokinetic targets. But a single participant in the dose-optimization studies experienced potential drug-induced liver injury. Though the overall rate of liver enzyme elevations across the program was comparable to other drugs in the class, Pfizer discontinued development in April 2025 citing the liver signal.
This decision was significant — it showed that even with competitive efficacy data, a safety signal in a single patient can end a program when the market already has approved alternatives. It also removed a potential lower-cost competitor from the pipeline.
Oral Semaglutide 50 mg
Phase 3 CompleteThe OASIS clinical program tested oral semaglutide at both 25 mg and 50 mg. The 25 mg dose became the Wegovy pill. The 50 mg dose showed even greater weight loss in trials but has not yet been submitted for FDA approval, and Novo Nordisk has not publicly committed to a specific regulatory submission timeline for this higher dose.
If approved, a 50 mg oral semaglutide could deliver weight loss closer to the injectable Wegovy HD (7.2 mg) level, potentially reaching 17–20% in adherent patients. However, it would still require the same fasting protocol as the 25 mg Wegovy pill.
Lotiglipron
DiscontinuedLotiglipron was Pfizer's other oral GLP-1 candidate. It was withdrawn from development after early-phase clinical trials showed elevated liver enzymes, indicating potential liver toxicity — the same type of signal that ultimately also contributed to danuglipron's discontinuation. This was an earlier casualty in Pfizer's oral GLP-1 efforts.
What the Pipeline Tells Us
Several patterns emerge from the current development landscape.
The next breakthrough will likely come from combination mechanisms, not better GLP-1 agonism alone. Oral amycretin (GLP-1 + amylin) is the most advanced dual-mechanism oral drug. The injectable pipeline already includes triple agonists like retatrutide (GLP-1 + GIP + glucagon) producing 24%+ weight loss — oral versions of these multi-mechanism approaches would be transformative, but they're further out.
Liver toxicity is the recurring killer for oral GLP-1 small molecules. Both of Pfizer's candidates died from liver signals. This may be a class-level concern for certain chemical scaffolds and will be closely watched as newer small molecules advance.
The fasting-vs-flexibility divide will persist. Peptide-based oral drugs (semaglutide) will continue to need SNAC-type technology and fasting protocols. Small-molecule drugs (orforglipron-type compounds) won't. Future combination drugs could go either way depending on their molecular structure.
What This Means for Patients Today
If you're considering an oral GLP-1 for weight loss, the decision in 2026 is between the Wegovy pill and Foundayo. The pipeline drugs are years away, and early-stage clinical data — however promising — regularly fails to hold up in larger, longer trials.
That said, the direction is clear: oral obesity medications are getting more effective, more convenient, and more numerous. Competition is driving down prices and expanding access. If you start on one of today's oral GLP-1s and a better option emerges in a few years, switching is a conversation you can have with your doctor then — treatment isn't permanent.
The Bottom Line
Oral amycretin is the pipeline drug to watch — a dual-mechanism pill from Novo Nordisk already in Phase 3 with early data suggesting 15–22% weight loss. But it's likely 3–4 years from FDA approval at best.
Pfizer's two oral GLP-1 candidates both failed due to liver toxicity signals, removing potential competitors and highlighting the development risks in this space. AstraZeneca's elecoglipron is early-stage but showing intriguing short-term results.
For now, the choice is between two strong options that exist today — not promising candidates that may or may not materialize years from now.